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Editorial: Looking for Justice from the Health Industry  
Doris Schroeder and Julie Cook  
 
 
“Dumping” is a predatory activity which increases personal or group gain at the expense of 
others. For instance, the price dumping of goods into a market at below-cost prices aims at 
the bankruptcy of competitors and thereby at a future monopoly. Social dumping can refer 
to using uninsured labor to reduce costs. Environmental dumping involves the transport of 
waste from one country to another (for instance, nuclear waste) where environmental laws 
are less strict.  
 
The term “ethics dumping” has been created by the Science with and for Society unit of the 
European Commission to describe double standards in research.  
 
Due to the progressive globalization of research activities, the risk is higher that 
research with sensitive ethical issues is conducted by European organizations outside 
the E.U. in a way that would not be accepted in Europe from an ethical point of view. 
This exportation of these noncompliant research practices is called “ethics dumping.”1 
 
It occurs mainly in three ways. First, when research participants and/or resources in low- and 
middle-income countries (LMICs) are exploited intentionally, for instance because research 
can be undertaken in a LMIC that would be prohibited in a high-income country. This aligns 
with environmental dumping dynamics; locations with less restrictive laws and regulations 
are actively sought in order to move research from one country to another. Second, 
exploitation can occur due to insufficient ethics awareness on the part of the researcher or 
their home institutions: the researcher is unaware of applying double standards. For instance, 
when undertaking research on highly vulnerable indigenous populations, it is standard 
practice to obtain group or community consent before approaching individuals.2 But a 
researcher/institution from a high-income country (HIC) may not be aware of this 
requirement due to lack of experience. Third, and relatedly, lack of researcher awareness can 
intersect with low research governance capacity in the host nation. The ethics committee in 
the host country should know about the group consent requirements, for example, but due 
to capacity issues, is not able to intervene in research and request necessary changes to a 
protocol.  
 
A wide range of ethics dumping cases have been described in a recent book.3 To give some 
examples: cultural prohibitions may be ignored in research with vulnerable populations; the 
standard of care may be misconstrued, putting research participants at unnecessary risk; 
benefit sharing may not take place; new technologies may be tested in settings with less 
public resistance due to lack of information; ethics approval may be sought retrospectively; 
or research participants may not be insured for harm incurred during a study.  
 
This symposium of four papers focuses on health research undertaken by the private sector. 
“Working Together to Make the World a Healthier Place—Desiderata for the Pharmaceutical 
Industry” (Klaus Leisinger and Kate Chatfield) links pharmaceutical research to the United 
Nations Sustainable Development Agenda and the newly emerging concept of responsible 
research and innovation4 (RRI) to build a hierarchy of obligations based on Ralf Dahrendorf’s 
work. They conclude that the adoption of RRI could prove to be an effective way of building 
trust in the research and innovation activities of pharmaceutical companies with the 
assurance that such activities are socially acceptable, desirable, and sustainable. 
 
In “Continued Access to Investigational Medicinal Products for Clinical Trial Participants—An 
Industry Approach,” Ariella Kelman, Anna Kang, and Brian Crawford describe an industry 
approach to a long-standing and complex problem in equitable research relationships. In 
2000, at the 52nd World Medical Association General Assembly in Edinburgh, posttrial 
obligations were added to the Declaration of Helsinki. In its current version, Article 34 of the 
Declaration of Helsinki requires that: 
 
In advance of a clinical trial, sponsors, researchers and host country governments 
should make provisions for posttrial access for all participants who still need an 
intervention identified as beneficial in the trial. This information must also be 
disclosed to participants during the informed consent process.5 
 
To realize posttrial access to successfully tested drugs is fraught with difficulties.6 The Roche 
approach, developed in conjunction with bioethicists and patient advocates, is described 
theoretically and practically using an example of the investigational medicine Etrolizumab. It 
is clear that the close collaboration of all stakeholders is vital to agreeing on a feasible policy 
and implementation. Societal and stakeholder engagement is one of the key action points of 
RRI, the importance of which is confirmed by the “Roche Global Policy on Continued Access 
to Investigational Medicinal Products.” 
 
“Healthy Volunteers For Clinical Trials in Resource-Poor Settings: National Registries Can 
Address Ethical and Safety Concerns” (Francois Bompart) is     a new initiative by the Sanofi 
Bioethics Committee in collaboration with the TRUST project.7 The paper outlines why healthy 
volunteers are a particularly vulnerable group in medical research, especially in LMICs. One 
of the most worrying concerns is concealed participation in multiple trials. Highly interesting 
data are provided about the number of healthy volunteers involved in trials worldwide; most 
are involved in pharmacokinetic rather than “first-in-human” studies. To protect healthy 
volunteers from harm, the author advocates for the setting up of national healthy volunteer 
registries as already established in France and the U.K. 
 
To provide insights into contrasting perspectives, Kalypso Iordanou analyzes the reluctance 
of small enterprises involved in health research to undertake research involving patients. 
According to interviews and literature research, some small enterprises avoid involving 
stakeholders, especially patients, in their research due to the high expected costs and the 
difficulty to satisfy patient expectations. 
 
The United Nations Sustainable Development Agenda is likely to be the most ambitious 
activity of our generation towards worldwide justice and equality. Goal No. 3, “Ensure healthy 
lives and promote well-being for all at all ages,” requires collaboration of all stakeholders, 
private and public. The pharmaceutical industry and its contribution towards the health and 
well-being of people around the world can and should play an active role in this process.  
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